[Form 3] Mural Oncology plc Initial Statement of Beneficial Ownership

Rhea-AI Filing Summary

Trium Capital LLP filed an SEC Form 3 disclosing initial beneficial ownership in Mural Oncology plc (MURA US). The filing reports 1,760,097 shares of MURA held directly. The event date listed is 08/22/2025 and the form is signed by Fredrik Ostlund on 09/02/2025. The filing identifies the reporting person as a Director.

Insights

Securities Analyst

TL;DR: Routine initial ownership disclosure showing a director with 1,760,097 directly held MURA shares.

The Form 3 is a standard Section 16 filing that provides transparency about insider holdings. It lists Trium Capital LLP as the reporting entity and reports 1,760,097 shares of Mural Oncology held directly. The form indicates the reporting person is a director and is signed by Fredrik Ostlund. There are no derivative holdings disclosed and no additional transaction details, so the filing serves solely to establish baseline insider ownership for regulatory purposes.

Corporate Governance Expert

TL;DR: A procedural disclosure establishing an insider ownership record; no new transactions or derivatives are reported.

This initial statement documents beneficial ownership in accordance with Section 16(a). It names the issuer and ticker, reports direct ownership of 1,760,097 shares, and identifies the reporter as a director. Absence of derivative positions or amendments suggests no complex compensation instruments are being disclosed here. The filing is informational and does not by itself indicate corporate actions or governance changes.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Trium Capital LLP

(Last) (First) (Middle)

60 GRESHAM STREET

(Street)

LONDON X0 EC2V 7BB

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
08/22/2025

3. Issuer Name and Ticker or Trading Symbol
Mural Oncology plc [ MURA US ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Mural Oncology Plc - MURA US EQUITY	1,760,097	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	Fredrik Ostlund	09/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does the Form 3 for MURA show?

The Form 3 discloses 1,760,097 shares of Mural Oncology plc (MURA US) owned directly by Trium Capital LLP and identifies the reporting person as a Director.

Who filed the Form 3 for Mural Oncology (MURA)?

The filing lists Trium Capital LLP as the reporting person and is signed by Fredrik Ostlund on 09/02/2025.

When is the event date reported on the MURA Form 3?

The date of the event requiring the statement is shown as 08/22/2025.

Are any derivative securities disclosed in this Form 3 for MURA?

No. Table II for derivative securities contains no entries; the filing shows only non-derivative equity ownership.

Is the reported ownership direct or indirect?

The filing explicitly reports the 1,760,097 shares as held directly.